MiMedx Announces Nationwide Launch of AmnioFix® Injectable at American Academy of Orthopaedic Surgeons Annual Meeting
SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announces the nationwide launch of AmnioFix® Injectable, the Company's newest tissue offering. MiMedx is formally unveiling AmnioFix® Injectable today during the first day of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting being held in San Francisco, California.
AmnioFix® Injectable is an allograft composed of micronized amniotic tissue, uniquely processed to optimize surgical performance and ease of use. The Company's proprietary Purion™ process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue. The result is an injectable tissue that offers surgeons a clear advantage due to its natural ability to reduce inflammation at the injection site and enhance soft tissue healing. Another significant advantage for physicians is the five-year, room temperature shelf life of AmnioFix® Injectable.
In addition to AmnioFix® Injectable, MiMedx is also highlighting AmnioFix® Wrap for both nerve and tendon applications. AmnioFix® Wrap is another of the MiMedx tissue offerings from the Company's AmnioFix® technology platform. AmnioFix® Nerve Wrap, an allograft from amniotic tissue that is utilized for various nerve repair surgical procedures, was formally launched during 2011. The Company's newest AmnioFix® Wrap allograft is designed for both nerve and tendon repair surgical procedures.
AmnioFix® Wrap is a composite allograft structure of amniotic membrane layers, uniquely processed through the Company's proprietary Purion™ process to optimize surgical performance and ease of use. For use as an in-vivo wrap in peripheral nerve and tendon trauma, AmnioFix® Wrap provides a protective barrier and contributes to the three phases of the natural healing process. . . inflammatory phase, proliferation phase and remodeling phase. In-vivo studies have confirmed that the properties of amniotic membrane help to reduce scar tissue formation and scar attachments to injured/repaired nerves and tendons.
Parker H. "Pete" Petit, Chairman and CEO, said, "During the conference, we are exhibiting the Company's full suite of biomaterial platform technologies developed for use in soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine. We are expanding our presence at the AAOS in order to serve the growing interests among physicians for minimally manipulated tissue offerings that address the clinical efficacy and cost effectiveness needs of these critical areas of healthcare."
At the AAOS meeting, MiMedx is located at Booth 2309, and the Company's team of executives and scientists are demonstrating the many potential applications using the AmnioFix® Injectable and AmnioFix® Wrap tissue allografts. "We are very pleased to be able to take advantage of this outstanding forum for physicians and scientists to gather and witness the remarkable potential of our AmnioFix® technology for numerous medical applications in the areas of soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine," commented Bill Taylor, President and COO.
Joining Pete Petit and Bill Taylor at the AAOS meeting are John Daniel, President and Founder of Surgical Biologics, Don Fetterolf, M.D., MiMedx Chief Medical Officer, Mike Carlton, Vice President of Global Sales, and other Scientific and Sales & Marketing members of the MiMedx executive team.
Throughout the conference, which is being held at the Moscone Center in San Francisco, MiMedx is also sponsoring various individual and small group meetings with physicians and scientists to discuss and demonstrate the benefits and potential of its tissue offerings from the Company's AmnioFix® technology platform, as well as its product offerings from the Company's HydroFix®, technology platform.
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion™ process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 60,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the growing interests among physicians for the Company's minimally manipulated tissue offerings that address the soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine areas of healthcare. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the growing interests among physicians for the Company's tissue offerings may not materialize as anticipated and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2010, and its most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.